Tyra Biosciences (NASDAQ: TYRA) director exercises 67,467 options, sells and returns shares

Q: What insider transactions did Tyra Biosciences (TYRA) director Gilla Kaplan report?

Director Gilla Kaplan reported exercising stock options for 67,467 shares of Tyra Biosciences common stock at $2.25 per share, combined with related dispositions and sales. These transactions occurred over March 25–26, 2026, and are disclosed as routine equity award exercises.

Q: How many Tyra Biosciences (TYRA) shares did Gilla Kaplan sell in the open market?

Gilla Kaplan sold 14,295 shares of Tyra Biosciences common stock in open-market or private transactions. The weighted average sale price was $36.9714 per share, with individual trades executed between $36.95 and $37.11, as described in the weighted-average pricing footnote.

Q: What does the disposition to issuer mean in the Tyra Biosciences (TYRA) Form 4?

The filing shows a disposition to the issuer of 53,172 shares of common stock at $37.7483 per share. This is coded as a disposition to the company rather than an open-market sale, typically reflecting shares returned to Tyra Biosciences in connection with the option exercise.

Q: Were the Tyra Biosciences (TYRA) stock options exercised by Gilla Kaplan fully vested?

Yes. A footnote states the options were “Fully vested” at the time of exercise. Kaplan exercised options covering 67,467 underlying shares at an exercise price of $2.25 per share, then combined those exercises with both an open-market sale and a disposition to the issuer.

Q: What prices were involved in Gilla Kaplan’s Tyra Biosciences (TYRA) transactions?

Kaplan exercised options at $2.25 per share, sold 14,295 shares at a weighted average of $36.9714, and disposed of 53,172 shares to the issuer at $37.7483 per share. Footnotes clarify sale prices ranged between $36.95 and $38.125 across multiple trades.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Tyra Biosciences director Gilla Kaplan reported option exercises and related share dispositions. Kaplan exercised stock options to acquire a total of 67,467 shares of common stock at an exercise price of $2.25 per share on March 25–26, 2026.

On March 25, 2026, Kaplan acquired 14,295 shares via option exercise and sold 14,295 shares of common stock in open-market transactions at a weighted average price of $36.9714 per share, with individual sale prices ranging from $36.95 to $37.11. On March 26, 2026, Kaplan exercised options for 53,172 shares and disposed of 53,172 shares back to the issuer at $37.7483 per share.

Following these transactions, Kaplan directly owned 28,231 shares of Tyra Biosciences common stock. The exercised options were reported as fully vested, and there are no remaining derivative positions shown in this filing.

Insider Trade Summary

Net Seller: 14,295 shares ($528,506)

Net Sell 6 txns

Insider KAPLAN GILLA

Role Director

Sold 14,295 shs ($529K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	53,172	$0.00	--
Exercise	Common Stock	53,172	$2.25	$120K
Disposition	Common Stock	53,172	$37.7483	$2.01M
Exercise	Stock Option (Right to Buy)	14,295	$0.00	--
Exercise	Common Stock	14,295	$2.25	$32K
Sale	Common Stock	14,295	$36.9714	$529K

Holdings After Transaction: Stock Option (Right to Buy) — 0 shares (Direct); Common Stock — 81,403 shares (Direct)

Footnotes (1)

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.95 to $37.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.25 to $38.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Fully vested.

Form 4 Insider Transactions: What Each Field Means →

03/27/2026 - 04:44 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

KAPLAN GILLA

(Last)

(First)

(Middle)

C/O TYRA BIOSCIENCES, INC.

2656 STATE STREET

(Street)

CARLSBAD

CALIFORNIA

92008

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Tyra Biosciences, Inc. [ TYRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/25/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/25/2026		M		14,295	A	$2.25	42,526	D
Common Stock	03/25/2026		S		14,295	D	$36.9714⁽¹⁾	28,231	D
Common Stock	03/26/2026		M		53,172	D	$2.25	81,403	D
Common Stock	03/26/2026		D		53,172	D	$37.7483⁽²⁾	28,231	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$2.25	03/25/2026		M			14,295	⁽³⁾	03/09/2031	Common Stock	14,295	$0	53,172	D
Stock Option (Right to Buy)	$2.25	03/26/2026		M			53,172	⁽³⁾	03/09/2031	Common Stock	53,172	$0	0	D

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.95 to $37.11. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.25 to $38.125. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Fully vested.

	/s/ Ali D. Fawaz, Attorney-in-Fact	03/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Tyra Biosciences (TYRA) director Gilla Kaplan report?

Director Gilla Kaplan reported exercising stock options for 67,467 shares of Tyra Biosciences common stock at $2.25 per share, combined with related dispositions and sales. These transactions occurred over March 25–26, 2026, and are disclosed as routine equity award exercises.

How many Tyra Biosciences (TYRA) shares did Gilla Kaplan sell in the open market?

Gilla Kaplan sold 14,295 shares of Tyra Biosciences common stock in open-market or private transactions. The weighted average sale price was $36.9714 per share, with individual trades executed between $36.95 and $37.11, as described in the weighted-average pricing footnote.

What does the disposition to issuer mean in the Tyra Biosciences (TYRA) Form 4?

The filing shows a disposition to the issuer of 53,172 shares of common stock at $37.7483 per share. This is coded as a disposition to the company rather than an open-market sale, typically reflecting shares returned to Tyra Biosciences in connection with the option exercise.

How many Tyra Biosciences (TYRA) shares does Gilla Kaplan hold after these transactions?

After completing the option exercises, sale, and disposition, Gilla Kaplan directly holds 28,231 shares of Tyra Biosciences common stock. This post-transaction balance is reported in the Form 4 and reflects Kaplan’s remaining direct ownership position following the March 2026 activities.

Were the Tyra Biosciences (TYRA) stock options exercised by Gilla Kaplan fully vested?

Yes. A footnote states the options were “Fully vested” at the time of exercise. Kaplan exercised options covering 67,467 underlying shares at an exercise price of $2.25 per share, then combined those exercises with both an open-market sale and a disposition to the issuer.

What prices were involved in Gilla Kaplan’s Tyra Biosciences (TYRA) transactions?

Kaplan exercised options at $2.25 per share, sold 14,295 shares at a weighted average of $36.9714, and disposed of 53,172 shares to the issuer at $37.7483 per share. Footnotes clarify sale prices ranged between $36.95 and $38.125 across multiple trades.